Search

TRGFT-201

[L64070] The HSPCs engraft in the bone marrow to reconstitute the blood and immune system, while the purified Tregs, given before the Tcons, suppress alloreactivity to reduce graft-versus-host disease … [L64070,L64071] Orca-T was approved by the FDA on June 30, 2026 for use in matched-donor hematopoietic stem cell transplantation with a myeloablative preparative regimen, for hematopoietic and immunologic

Peppermint

Peppermint allergenic extract is used in allergenic testing.

Desoxyribonuclease

The enzyme's cofactor is reported to be magnesium (or manganese) ions, although the optimal concentration of the ion is independent of the enzyme concentration [A31251].

Dosulepin

Dosulepin (INN, BAN) formerly known as dothiepin (USAN), is a tricyclic antidepressant with anxiolytic properties that is used in several European and South Asian countries, as well as Australia, South

Gemtuzumab ozogamicin

in combination with chemotherapy or on its own [L941]. … By binding to the CD33 antigen on tumors, the cytotoxic agent blocks the growth of cancerous cells and causes cell death.

Tocopherol

The classification of the tocopherol molecules is designated depending on the number and position of the methyl substituent in the chromanol ring.

Margetuximab

[A225751, A225756, A225766, A191829, L27986] Margetuximab binds to the same epitope on the HER2 extracellular domain and induces the same effects as [trastuzumab]. … [A225751, A225756, A225766, A191829, L27986] Margextuximab was granted FDA approval on December 16, 2020, and is currently marketed under the trademark MARGENZA™ by MacroGenics, Inc.[L27986]

Edaravone

[L44017] Edaravone was initially granted orphan designation by the European Medicines Agency on June 19, 2015 [L44007] and was under regulatory review in Europe. … However, the drug manufacturer, Mitsubishi Tanabe Pharma, withdrew the Marketing Authorization Application (MAA) for edaravone from the European market on May 24, 2019, in response to the request made

Maralixibat

It was granted FDA approval on 29 September 2021. … [L44396] On July 21, 2023, maralixibat was also approved by Health Canada.[L47541]

Alloin